BRPI0606774A2 - método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 - Google Patents

método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2

Info

Publication number
BRPI0606774A2
BRPI0606774A2 BRPI0606774-3A BRPI0606774A BRPI0606774A2 BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2 BR PI0606774 A BRPI0606774 A BR PI0606774A BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2
Authority
BR
Brazil
Prior art keywords
cell carcinoma
renal cell
treating
human patient
therapy
Prior art date
Application number
BRPI0606774-3A
Other languages
English (en)
Inventor
Laurence Elias
Gary Witherell
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of BRPI0606774A2 publication Critical patent/BRPI0606774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO PARA O TRATAMENTO DE UM PACIENTE HUMANO QUE TEM CARCINOMA DE CéLULA RENAL E USO DE IL-2. São revelados métodos para o tratamento de carcinoma de célula renal que usam baixas doses de IL-2. Em particular, a invenção relaciona-se a métodos de tratamento de carcinoma de célula renal metastático em pacientes que têm insuficiência renal e/ou intolerantes à terapia com alta dose de IL-2. O regime terapêutico aqui descrito inibe de forma significativa o crescimento do tumor com toxicidade e efeitos colaterais adversos reduzidos comparado à terapia com alta dose de IL-2.
BRPI0606774-3A 2005-01-27 2006-01-27 método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 BRPI0606774A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
PCT/US2006/003116 WO2006081510A2 (en) 2005-01-27 2006-01-27 Methods for treating renal cell carcinoma

Publications (1)

Publication Number Publication Date
BRPI0606774A2 true BRPI0606774A2 (pt) 2009-07-14

Family

ID=36741121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606774-3A BRPI0606774A2 (pt) 2005-01-27 2006-01-27 método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2

Country Status (13)

Country Link
US (2) US20070014765A1 (pt)
EP (1) EP1846020B1 (pt)
JP (2) JP2008528621A (pt)
KR (1) KR20070102576A (pt)
CN (1) CN101132809A (pt)
AU (1) AU2006207987B2 (pt)
BR (1) BRPI0606774A2 (pt)
CA (1) CA2595959A1 (pt)
ES (1) ES2432141T3 (pt)
IL (1) IL184865A (pt)
MX (1) MX2007009012A (pt)
RU (1) RU2404795C2 (pt)
WO (1) WO2006081510A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370399A4 (en) * 2008-12-11 2013-05-22 Agency Science Tech & Res GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP3443979B2 (en) * 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
US9669071B2 (en) * 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
IL301612A (en) * 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology therapies with il-2 conjugates
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
ATE537842T1 (de) * 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms

Also Published As

Publication number Publication date
IL184865A0 (en) 2007-12-03
IL184865A (en) 2011-04-28
EP1846020B1 (en) 2013-08-21
AU2006207987B2 (en) 2011-09-15
AU2006207987A1 (en) 2006-08-03
JP2012046552A (ja) 2012-03-08
MX2007009012A (es) 2007-09-14
CA2595959A1 (en) 2006-08-03
US20100316595A1 (en) 2010-12-16
RU2404795C2 (ru) 2010-11-27
RU2007132125A (ru) 2009-03-10
JP2008528621A (ja) 2008-07-31
KR20070102576A (ko) 2007-10-18
US8012465B2 (en) 2011-09-06
WO2006081510A3 (en) 2007-01-18
US20070014765A1 (en) 2007-01-18
CN101132809A (zh) 2008-02-27
ES2432141T3 (es) 2013-11-29
WO2006081510A2 (en) 2006-08-03
EP1846020A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
WO2006081510A3 (en) Methods for treating renal cell carcinoma
Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials
Kopeina et al. Caloric restriction-A promising anti-cancer approach: From molecular mechanisms to clinical trials
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
BRPI0517976A (pt) métodos de tratamento
Rampino et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial
Marcenaro et al. Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor
Magno et al. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer
EA201270298A1 (ru) Способ лечения злокачественной опухоли
Lai et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer—a pilot study
Stellamans et al. Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
WO2005113720A3 (en) A strategy for designing patient-specific anti-cancer drugs
Brizel et al. Randomized phase III trial of radiation±Ethyol®(Amifostine) in patients with head and neck cancer
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]